Trusted Resources: Education
Scientific literature and patient education texts
Obesity is a Significant Susceptibility Factor for Idiopathic AA Amyloidosis
source: Amyloid: The International Journal of Experimental and Clinical Investigation
year: 2018
authors: Blank N, Hegenbart U, Dietrich S, Brune M, Beimler J, Röcken C, Müller-Tidow C, Lorenz HM, Schönland SO
summary/abstract:Background:
To investigate obesity as susceptibility factor in patients with idiopathic AA amyloidosis.
Methods:
Clinical, biochemical and genetic data were obtained from 146 patients with AA amyloidosis. Control groups comprised 40 patients with long-standing inflammatory diseases without AA amyloidosis and 56 controls without any inflammatory disease.
Findings:
Patients with AA amyloidosis had either familial Mediterranean fever (FMF) or long-standing rheumatic diseases as underlying inflammatory disease (n = 111, median age 46 years). However, in a significant proportion of patients with AA amyloidosis no primary disease was identified (idiopathic AA; n = 37, median age 60 years). Patients with idiopathic AA amyloidosis were more obese and older than patients with AA amyloidosis secondary to FMF or rheumatic diseases. Serum leptin levels correlated with the body mass index (BMI) in all types of AA amyloidosis. Elevated leptin levels of more than 30 µg/l were detected in 18% of FMF/rheumatic + AA amyloidosis and in 40% of patients with idiopathic AA amyloidosis (p = .018). Finally, the SAA1 polymorphism was confirmed as a susceptibility factor for AA amyloidosis irrespective of the type of the disease.
Conclusions:
Obesity, age and the SAA1 polymorphism are susceptibility factors for idiopathic AA amyloidosis. Recent advances in treatment of FMF and rheumatic disorders will decrease the incidence of AA amyloidosis due to these diseases. Idiopathic AA, however, might be an emerging problem in the ageing and increasingly obese population.
organization: University of Heidelberg, Germany; University of Kiel, GermanyDOI: 10.1080/13506129.2018.1429391
read more full text
Related Content
-
Secondary, AA, AmyloidosisSecondary, AA, amyloidosis is a rare sys...
-
What Is AA Amyloidosis?AA amyloidosis was previously known as s...
-
AA Amyloidosis: Pathogenesis and Targeted TherapyThe understanding of why and how protein...
-
ISA 2020 | Tocilizumab for AA Amyloidosishttps://www.youtube.com/watch?v=uALaB42R...
-
Systemic Amyloidosis From A (AA) to T (ATTR): A ReviewSystemic amyloidosis is a rare protein m...
-
ISA 2020 | AA Amyloidosis Managementhttps://www.youtube.com/watch?v=gENrlj8U...
-
AA AmyloidosisAA amyloidosis, or secondary amyloidosis...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.